Latest Royalty Income News

Neuren Pharmaceuticals reported a 15% rise in 2025 royalties from DAYBUE®, boosted by strong US sales and a new powder formulation launch. The company is progressing its pivotal Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome and reassessing capital management amid solid cash reserves.

DGR Global has secured a $3 million investment in Savannah Goldfields, combining a tiered gold royalty with a 4.5% equity stake. The deal aims to tap into Savannah’s North Queensland gold assets and fund exploration, following DGR’s recent SolGold exit.

Neuren Pharmaceuticals saw a 20% jump in Q1 2026 DAYBUE net sales to US$101 million, with royalties up 23%. The Japan trofinetide trial has been fast-tracked, and the new powder formulation DAYBUE STIX gains early traction.

Cambium Bio has clinched FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development complexity, while bolstering its cash position through a A$2.4 million strategic placement by major shareholder ZYBT.

Anagenics Limited delivered a third quarter operational performance aligned with budget following its restructuring, with cash outflows narrowing and its Bouf Haircare brand generating robust royalty revenue.

Gullewa Limited progresses with Hunter Valley property construction, submits a critical mining lease extension for South Darlot, and boosts its Central Iron Ore stake through a rights issue.

Neuren Pharmaceuticals reported a solid A$30.4 million net profit in 2025, powered by a 15% rise in DAYBUE® royalties. The company is progressing its NNZ-2591 Phase 3 trial for Phelan-McDermid syndrome and has initiated a share buy-back amid perceived undervaluation.

Moho Resources has finalised the sale of its Silver Swan North Project, receiving an initial $500,000 payment and securing future milestone and royalty income. The deal strengthens Moho’s balance sheet as it intensifies exploration at its Bush Chook Gold Project in Western Australia.

Talisman Mining has confirmed significant near-surface gold mineralisation at its Walkers Hill and East Peak Hill projects in NSW through recent aircore drilling, alongside receiving $0.79 million in iron ore royalties and maintaining a solid cash position.

Fitzroy River Corporation has received a significant payment from Tasman Mining as part of an option exercise to acquire its royalty on the Snowy River Gold Project in New Zealand. The funds are currently held in escrow pending confirmation of key project milestones.

Neuren Pharmaceuticals reports a 15% rise in 2025 royalties from its partner Acadia’s DAYBUE sales, with strong 2026 guidance signalling further growth. The launch of a new powder formulation and ongoing regulatory efforts in Europe and Japan add to the momentum.

Red Hill Minerals highlights a strong dividend-paying model backed by diversified royalties and a vigorous 2026 exploration agenda at the RIU Explorers Conference.